|
BRD1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62536650805123E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
6.06559247273708E-12 |
| Normal-vs-Stage2 |
1.01020000142782E-08 |
| Normal-vs-Stage3 |
9.43689570931383E-15 |
| Normal-vs-Stage4 |
1.81277215460796E-12 |
| Stage1-vs-Stage2 |
3.791400E-01 |
| Stage1-vs-Stage3 |
1.210170E-02 |
| Stage1-vs-Stage4 |
1.236270E-02 |
| Stage2-vs-Stage3 |
3.849800E-01 |
| Stage2-vs-Stage4 |
2.158200E-01 |
| Stage3-vs-Stage4 |
5.791000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
7.32747196252603E-15 |
| Normal-vs-AfricanAmerican |
2.00290000029746E-07 |
| Normal-vs-Asian |
8.16030000017065E-07 |
| Caucasian-vs-AfricanAmerican |
4.293600E-01 |
| Caucasian-vs-Asian |
3.793000E-01 |
| AfricanAmerican-vs-Asian |
2.667600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.79880024606416E-10 |
| Normal-vs-Female |
1.62492241884138E-12 |
| Male-vs-Female |
3.236000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
7.16979808856877E-11 |
| Normal-vs-Age(41-60Yrs) |
5.56332757639666E-13 |
| Normal-vs-Age(61-80Yrs) |
1.62525548574877E-12 |
| Normal-vs-Age(81-100Yrs) |
5.374100E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.392800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.549920E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.026000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.031600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.531400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.650600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.323950E-03 |
| Classical-VS-Follicular |
8.43140000000853E-05 |
| Classical-VS-Other |
9.485800E-01 |
| Classical-VS-Normal |
1.33739685992396E-11 |
| Tall-VS-Follicular |
9.718800E-01 |
| Tall-VS-Other |
4.055200E-01 |
| Tall-VS-Normal |
4.50128823104023E-12 |
| Follicular-VS-Other |
4.076000E-01 |
| Follicular-VS-Normal |
1.64035451888367E-12 |
| Other-VS-Normal |
1.347040E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
9.99200722162641E-14 |
| Normal-vs-N1 |
2.56569987477917E-10 |
| N0-vs-N1 |
9.391600E-01 |
|
|
